Faster, cheaper and more reliable, such is the promise of the patented SwiMR (Switchable Membrane Reporter) technology used by the Diaorigin laboratory. Applied since 2012 in the antibody industry, this technology allows the rapid development of stable cell lines. “This is an innovative technology that evolves the process and reduces the time for antibody development” explains Dr. Yongjin Wang, a former researcher at the Pasteur Institute and president of Diaorigin Technology in Paris. “It also reduces labor and laboratory consumables by 80% and therefore the cost of manufacturing”. With several SwiMR cloning vectors that adapt to all types of antigens and antibodies, this technology allows the construction of stable mini-pool cells in less than one month, as well as the monoclonal cell line in less than three months.
Innovative technology and alternative to existing solutions
Created in Shanghai in 2019, the Diaorigin laboratory has also had a branch in Paris since 2020, which is mainly concerned with the commercialization and development of this SwiMR technology. His goal now is to apply this innovative process to the pharmaceutical industry to save costs, promote research and be more efficient.
This content was produced in association with OpenMedias. The BFM Business editorial team was not involved in the production of this content.
Source: BFM TV
